CLINICAL TRIALS PROFILE FOR ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

All Clinical Trials for acetaminophen; propoxyphene hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00240786 ↗	An Effectiveness and Safety Study of Two Doses of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee	Completed	Johnson & Johnson Consumer and Personal Products Worldwide	Phase 3	2002-04-01	The purpose of this study is to determine the safety and effectiveness of 650 mg and 1300 mg acetaminophen extended release given three times a day for the relief of signs and symptoms of osteoarthritis of the hip or knee for a period of 12 weeks.
NCT00240799 ↗	An Effectiveness and Safety Study of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee.	Completed	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Phase 3	1969-12-31	The purpose of this study is to evaluate acetaminophen extended release (3900 mg/day) compared to placebo for safety and effectiveness in the relief of signs and symptoms of osteoarthritis of the hip or knee over 12 weeks
NCT00240799 ↗	An Effectiveness and Safety Study of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee.	Completed	Johnson & Johnson Consumer and Personal Products Worldwide	Phase 3	1969-12-31	The purpose of this study is to evaluate acetaminophen extended release (3900 mg/day) compared to placebo for safety and effectiveness in the relief of signs and symptoms of osteoarthritis of the hip or knee over 12 weeks

Clinical Trial Conditions for acetaminophen; propoxyphene hydrochloride

Condition Name

Condition Name for acetaminophen; propoxyphene hydrochloride
Intervention	Trials
Osteoarthritis	2
Atrial Fibrillation	1
Bariatric Surgery Candidate	1

Condition MeSH

Condition MeSH for acetaminophen; propoxyphene hydrochloride
Intervention	Trials
Osteoarthritis, Hip	2
Osteoarthritis	2
Atrial Fibrillation	1

Clinical Trial Locations for acetaminophen; propoxyphene hydrochloride

Trials by Country

Trials by Country for acetaminophen; propoxyphene hydrochloride
Location	Trials
Egypt	1
Brazil	1
United States	1

Trials by US State

Trials by US State for acetaminophen; propoxyphene hydrochloride
Location	Trials
New York	1

Clinical Trial Progress for acetaminophen; propoxyphene hydrochloride

Clinical Trial Phase

Clinical Trial Phase for acetaminophen; propoxyphene hydrochloride
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	2
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for acetaminophen; propoxyphene hydrochloride
Clinical Trial Phase	Trials
Completed	3
Terminated	1
Suspended	1

Clinical Trial Sponsors for acetaminophen; propoxyphene hydrochloride

Sponsor Name

Sponsor Name for acetaminophen; propoxyphene hydrochloride
Sponsor	Trials
Johnson & Johnson Consumer and Personal Products Worldwide	2
University of Rochester	1
Fundação de Amparo à Pesquisa do Estado de São Paulo	1

Sponsor Type

Sponsor Type for acetaminophen; propoxyphene hydrochloride
Sponsor	Trials
Industry	4
Other	4

Acetaminophen + Propoxyphene Hydrochloride: Clinical Trials Update, Market Analysis, and Projection

Last updated: May 7, 2026

What is the current clinical-trials status for acetaminophen + propoxyphene hydrochloride?

No complete, current clinical-trials picture can be produced from the information available in this context. A reliable status update requires trial-by-trial sourcing (e.g., ClinicalTrials.gov records) with study identifiers, dates, and outcomes.

What is the market basis for acetaminophen + propoxyphene hydrochloride?

No complete, current market analysis can be produced from the information available in this context. A credible market view requires sales/volume inputs and segmentation by geography, channel, payer status, and label scope.

What is the projection for acetaminophen + propoxyphene hydrochloride?

No complete projection can be produced from the information available in this context. A defensible forecast requires baseline market size, dynamics by region and formulary access, and any legal or regulatory headwinds tied to the product.

What do investors and R&D teams use to validate direction on this asset?

A workable validation workflow depends on market and clinical primary sources (registry and sales databases) and must include:

• Trial-level status: recruiting vs active vs completed, primary completion dates, and efficacy/safety endpoints
• Label scope and regulatory history: country-by-country status and any restrictions
• Market inputs: prescription volumes, average selling price, competitive set, and formulary restrictions
• Forecast drivers: demand elasticity, substitution effects, and discontinuation risk

Key Takeaways

• A complete clinical-trials update cannot be produced here without trial registry data.
• A complete market analysis cannot be produced here without quantified sales and access inputs.
• A complete forecast cannot be produced here without a baseline market model and regulatory context.

FAQs

1. Why can’t a clinical-trials update be produced? Trial-level identification and current status require primary registry records and dated outcomes.
2. Why can’t a market projection be produced? Projections require quantified baseline market size and region/channel segmentation.
3. Is this a combination product with a constrained evidence base? Evidence and regulatory status must be checked in each market using label- and trial-level documentation.
4. What inputs typically drive demand for this type of analgesic? Prescribing patterns, formulary placement, safety communications, and competitor substitution.
5. What sources are typically used for diligence? Clinical trial registries and market/sales datasets with label-specific mapping.

References

No cited sources were provided in the prompt.